Target Price | $15.73 |
Price | $8.85 |
Potential |
77.78%
register free of charge
|
Number of Estimates | 15 |
15 Analysts have issued a price target 10x Genomics Inc - Ordinary Shares - Class A 2026 .
The average 10x Genomics Inc - Ordinary Shares - Class A target price is $15.73.
This is
77.78%
register free of charge
$26.00
193.79%
register free of charge
$12.00
35.59%
register free of charge
|
|
A rating was issued by 20 analysts: 8 Analysts recommend 10x Genomics Inc - Ordinary Shares - Class A to buy, 10 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the 10x Genomics Inc - Ordinary Shares - Class A stock has an average upside potential 2026 of
77.78%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 610.79 | 610.52 |
1.28% | 0.04% | |
EBITDA Margin | -24.31% | -26.18% |
4.95% | 7.69% | |
Net Margin | -30.43% | -30.19% |
29.37% | 0.80% |
17 Analysts have issued a sales forecast 10x Genomics Inc - Ordinary Shares - Class A 2025 . The average 10x Genomics Inc - Ordinary Shares - Class A sales estimate is
This results in the following potential growth metrics:
11 Analysts have issued an 10x Genomics Inc - Ordinary Shares - Class A EBITDA forecast 2025. The average 10x Genomics Inc - Ordinary Shares - Class A EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
18 10x Genomics Inc - Ordinary Shares - Class A Analysts have issued a net profit forecast 2025. The average 10x Genomics Inc - Ordinary Shares - Class A net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.52 | -1.51 |
30.28% | 0.66% | |
P/E | negative | |
EV/Sales | 1.26 |
18 Analysts have issued a 10x Genomics Inc - Ordinary Shares - Class A forecast for earnings per share. The average 10x Genomics Inc - Ordinary Shares - Class A EPS is
This results in the following potential growth metrics and future valuations:
10x Genomics Inc - Ordinary Shares - Class A...
Analyst | Rating | Action | Date |
---|---|---|---|
Citigroup |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
Barclays |
Locked
➜
Locked
|
Locked | Feb 14 2025 |
Morgan Stanley |
Locked
➜
Locked
|
Locked | Feb 14 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Feb 13 2025 |
Leerink Partners |
Locked
➜
Locked
|
Locked | Feb 13 2025 |
Citigroup |
Locked
➜
Locked
|
Locked | Feb 13 2025 |
Stifel |
Locked
➜
Locked
|
Locked | Feb 13 2025 |
Analyst Rating | Date |
---|---|
Locked
Citigroup:
Locked
➜
Locked
|
Mar 04 2025 |
Locked
Barclays:
Locked
➜
Locked
|
Feb 14 2025 |
Locked
Morgan Stanley:
Locked
➜
Locked
|
Feb 14 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Feb 13 2025 |
Locked
Leerink Partners:
Locked
➜
Locked
|
Feb 13 2025 |
Locked
Citigroup:
Locked
➜
Locked
|
Feb 13 2025 |
Locked
Stifel:
Locked
➜
Locked
|
Feb 13 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.